Mahin GHOLIPOUR, Javad MIKAELI, Seyed Javad MOWLA, Mohammad Reza BAKHTIARIZADEH, Marie SAGHAEIAN JAZI, Naeme JAVID, Narges FAZLOLLAHI, Masoud KHOSHNIA, Naser BEHNAMPOUR, Abdolvahab MORADI

Identification of differentially expressed microRNAs in primary esophageal achalasia by next-generation sequencing

Molecular knowledge regarding the primary esophageal achalasia is essential for the early diagnosis and treatment of this neurodegenerative motility disorder. Therefore, there is a need to find the main microRNAs (miRNAs) contributing to the mechanisms of achalasia. This study was conducted to determine some patterns of deregulated miRNAs in achalasia. This case-control study was performed on 52 patients with achalasia and 50 nonachalasia controls. The miRNA expression profiling was conducted on the esophageal tissue samples using the next-generation sequencing (NGS). Differential expression of miRNAs was analyzed by the edgeR software. The selected dysregulated miRNAs were additionally confirmed using the quantitative reverse transcription polymerase chain reaction (qRT-PCR). Fifteen miRNAs were identified that were significantly altered in the tissues of the patients with achalasia. Among them, three miRNAs including miR-133a-5p, miR-143-3p, and miR-6507-5p were upregulated. Also, six miRNAs including miR-215-5p, miR-216a-5p, miR-216b-5p, miR-217, miR-7641 and miR-194-5p were downregulated significantly. The predicted targets for the dysregulated miRNAs showed significant disease-associated pathways like neuronal cell apoptosis, neuromuscular balance, nerve growth factor signaling, and immune response regulation. Further analysis using qRT-PCR showed significant down-regulation of hsa-miR-217 (p-value = 0.004) in achalasia tissue. Our results may serve as a basis for more future functional studies to investigate the role of candidate miRNAs in the etiology of achalasia and their application in the diagnosis and probably treatment of the disease.

Keywords:

Achalasia, microRNA, next-generation sequencing, expression profiling, bioinformatics,

PDF

___

Ahmad A, Zhang W, Wu M, Tan S, Zhu T (2018). Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes. Genes & Genomics 40: 243-251. doi: 10.1007/s13258-017-0624-6
Ates F, Vaezi MF (2015). The pathogenesis and management of achalasia: current status and future directions. Gut Liver 9: 449. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297. doi: 10.1016/S0092-8674(04)00045-5
Bolger A, Lohse M, Usadel B (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30: btu170. doi: 10.1093/bioinformatics/btu170
Chen D, Zhang D, Lu Y, Chen L, Zeng Z et al. (2015). microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. Oncotarget 6: 10868. doi: 10.18632/oncotarget.3451
De León A, De La Serna J, Santiago J, Sevilla C, Fernández‐arquero M et al. (2010). Association between idiopathic achalasia and IL23R gene. J Neurogastroenterol Motil 22: 734-e218. doi: 10.1111/j.1365-2982.2010.01497.x
Deng M, Tang H, Zhou Y, Zhou M, Xiong W et al. (2011). miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. Journalof Cell Science 124: 2997-3005. doi: 10.1242/jcs.085050
Dong S, Yin H, Dong C, Sun K, Lv P et al. (2016). Predictive value of plasma microRNA-216a/b in the diagnosis of esophageal squamous cell carcinoma. Disease Markers 2016. doi: 10.1155/2016/1857067
Dughera L, Chiaverina M, Cacciotella L, Cisarò F (2011). Management of achalasia. Clinical and Experimental Gastroenterology 4: 33. doi: 10.2147/CEG.S11593
Fang Y, Fang D, Hu J (2012). MicroRNA and its roles in esophageal cancer. Medical Science Monitor 18: RA22-RA30. doi: 10.12659/MSM.882509
Farrokhi F, Vaezi MF (2007). Idiopathic (primary) achalasia. Orphanet Journal of Rare Diseases 2: 38. doi: 10.1186/1750-1172-2-38
Friedländer MR, Mackowiak SD, Li N, Chen W, Rajewsky N (2011). miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Research 40: 37-52. doi: 10.1093/nar/gkr688
Furer V, Greenberg JD, Attur M, Abramson SB, Pillinger MH (2010). The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clinical Immunology 136:1-15. doi: 10.1016/j.clim.2010.02.005
Furuzawa-Carballeda J, Torres-Landa S, Valdovinos MÁ, Coss-Adame E, Del Campo LAM et al. (2016). New insights into the pathophysiology of achalasia and implications for future treatment. World Journal of Gastroenterology 22: 7892. doi: 10.3748/wjg.v22.i35.7892
Ghoshal UC, Daschakraborty SB, Singh R (2012). Pathogenesis of achalasia cardia. World Journal of Gastroenterology 18: 3050-3057. doi: 10.3748/wjg.v18.i24.3050
Grasso M, Piscopo P, Confaloni A, Denti MA (2014). Circulating miRNAs as biomarkers for neurodegenerative disorders. Molecules 19:c6891-6910. doi: 10.3390/molecules19056891
Hasanzadeh A, Mikaeli J, Elahi E, Mehrabi N, Etemadi A et al. (2010). Demographic, clinical features and treatment outcomes in 700 achalasia patients in Iran. Middle East Journal of Digestive Diseases 2:c91.
Hirano I (2006). Pathophysiology of achalasia and diffuse esophageal spasm. GI Motility online. doi: 10.1038/gimo22
Kahrilas PJ, Boeckxstaens G (2013). The spectrum of achalasia: lessons from studies of pathophysiology and high-resolution manometry. Gastroenterology 145: 954-965. doi: 10.1053/j.gastro.2013.08.038
Kahrilas PJ, Bredenoord A, Fox M, Gyawali C, Roman S et al. (2015). The Chicago Classification of esophageal motility disorders, v3. 0. Neurogastroenterology & Motility 27: 160-174. doi: 10.1111/nmo.12477
Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007). The role of site accessibility in microRNA target recognition. Nature Genetics 39: 1278. doi: 10.1038/ng2135
Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F et al. (2007). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. The EMBO Journal 26: 3169-3179. doi: 10.1038/sj.emboj.7601758
Kozomara A, Griffiths-Jones S (2013). miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Research 42: D68-D73. doi: 10.1093/nar/gkt1181
Kulski JK (2016). Next-generation sequencing—an overview of the history, tools, and “omic” applications. In: Kulski JK (editor). Next Generation Sequencing-Advances, Applications and Challenges. London, UK: IntechOpen, pp. 3-60.
Kye MJ, Inês do Carmo GG (2014). The role of miRNA in motor neuron disease. Frontiers in Cellular Neuroscience 8. doi: 10.3389/fncel.2014.00015
Li KKW, Pang JCS, Lau KM, Zhou L, Mao Y et al. (2013a). MiR‐383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathology 23: 413-425. doi: 10.1111/bpa.12014
Li P, Mao WM, Zheng ZG, Dong ZM, Ling ZQ (2013b). Down-regulation of PTEN expression modulated by dysregulated miR-21 contributes to the progression of esophageal cancer. Digestive Diseases and Sciences 58: 3483-3493. doi: 10.1007/s10620-013-2854-z
Lian J, Tian H, Liu L, Zhang X, Li W et al. (2010). Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death &Disease 1: e94. doi: 10.1038/cddis.2010.70
Liu F, Zhou S, Deng Y, Zhang Z, Zhang E et al. (2015). MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death & Disease 6: e1670. doi: 10.1038/cddis.2015.46
Martínez-Ramos R, García-Lozano J, Lucena J, Castillo-Palma M, García-Hernández F et al. (2014). Differential expression pattern of microRNAs in CD4+ and CD19+ cells from asymptomatic patients with systemic lupus erythematosus. Lupus 23: 353-359. doi: 10.1177/0961203314522335
Mohammadi-Yeganeh S, Paryan M, Samiee SM, Soleimani M, Arefian E et al. (2013). Development of a robust, low cost stem-loop real-time quantification PCR technique for miRNA expression analysis. Molecular Biology Reports 40: 3665-3674. doi: 10.1007/s11033-012-2442-x
Morris L, Veeriah S, Chan T (2010). Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 29: 3453-3464. doi: 10.1038/onc.2010.127
Motameny S, Wolters S, Nürnberg P, Schumacher B (2010). Next generation sequencing of miRNAs–strategies, resources and methods. Genes 1: 70-84.
Nawrocki EP, Burge SW, Bateman A, Daub J, Eberhardt RY et al. (2014). Rfam 12.0: updates to the RNA families database. Nucleic Acids Research 43: 130-137. doi: 10.1093/nar/gku1063
Palmieri O, Mazza T, Bassotti G, Merla A, Tolone S et al. (2019). microRNA‐mRNA network model in patients with achalasia. Neurogastroenterology & Motility 32. doi: 10.1111/nmo.13764
Palmieri O, Mazza T, Merla A, Fusilli C, Cuttitta A et al. (2016). Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. Scientific Reports 6: 31549. doi: 10.1038/srep31549
Park W, Vaezi MF (2005). Etiology and pathogenesis of achalasia: the current understanding. The American Journal of Gastroenterology 100: 1404-1414. doi: 10.1111/j.1572-0241.2005.41775.x
Qiu YQ (2013). KEGG Pathway Database. In: Dubitzky W., Wolkenhauer O., Cho KH., Yokota H. (eds) Encyclopedia of Systems Biology. Springer, New York, NY. doi: 10.1007/978-1-4419-9863-7_472
Qualman SJ, Haupt HM, Yang P, Hamilton SR (1984). Esophageal Lewy bodies associated with ganglion cell loss in achalasia: similarity to Parkinson’s disease. Gastroenterology 87: 848-856. Rehmsmeier M, Steffen P, Höchsmann M, Giegerich R (2004). Fast and effective prediction of microRNA/target duplexes. RNA 10: 1507-1517. doi: 10.1261/rna.5248604
Ruiz-de-León A, Mendoza J, Sevilla-Mantilla C, Arquero MF, Pérez-de-la-Serna J et al. (2002). Myenteric antiplexus antibodies and class II HLA in achalasia. Digestive Diseases and Sciences 47: 15-19.
Sadowski D, Ackah F, Jiang B, Svenson L (2010). Achalasia: incidence, prevalence and survival. A population‐based study. Neurogastroenterology & Motility 22: e256-e261. doi: 10.1111/j.1365-2982.2010.01511.x
Shoji H, Isomoto H, Yoshida A, Ikeda H, Minami H et al. (2017). MicroRNA-130a is highly expressed in the esophageal mucosa of achalasia patients. Experimental and Therapeutic Medicine 14: 898-904. doi: 10.3892/etm.2017.4598
Singh RP, Massachi I, Manickavel S, Singh S, Rao NP et al. (2013). The role of miRNA in inflammation and autoimmunity. Autoimmunity Reviews 12: 1160-1165. doi: 10.1016/j.autrev.2013.07.003
Sodikoff JB, Lo AA, Shetuni BB, Kahrilas PJ, Yang GY et al. (2016). Histopathologic patterns among achalasia subtypes. Neurogastroenterology & Motility 28:139-145. doi: 10.1111/nmo.12711
Sturm M, Hackenberg M, Langenberger D, Frishman D (2010). TargetSpy: a supervised machine learning approach for microRNA target prediction. BMC Bioinformatics 11: 292. doi: 10.1186/1471-2105-11-292
Tahamtan A, Inchley CS, Marzban M, Tavakoli‐Yaraki M, Teymoori‐Rad M et al. (2016). The role of microRNAs in respiratory viral infection: friend or foe? Reviews in Medical Virology 26: 389-407. doi: 10.1002/rmv.1894
Triadafilopoulos G, Patti MG, Gullo R, Pandolfino JE, Kahrilas PJ et al. (2012). The Kagoshima consensus on esophageal achalasia. Diseases of the Esophagus 25:337-348. doi: 10.1111/j.1442-2050.2011.01207.x
Vantrappen G, Hellemans J (1980). Treatment of achalasia and related motor disorders. Gastroenterology 79: 144-154. doi: 10.1016/0016-5085(80)90090-6
Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V et al. (2015). MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagnostic Pathology 10: 1. doi: 10.1186/s13000-015-0272-6
Wang B, Shen Z-l, Jiang K-w, Zhao G, Wang C-y et al. (2015a). MicroRNA-217 functions as a prognosis predictor and inhibits colorectal cancer cell proliferation and invasion via an AEG-1 dependent mechanism. BMC Cancer 15: 1. doi: 10.1186/s12885-015-1438-z
Wang C, Ji B, Cheng B, Chen J, Bai B (2014a). Neuroprotection of microRNA in neurological disorders (Review). Biomedical Reports 2: 611-619. doi: 10.3892/br.2014.297
Wang R-T, Xu M, Xu C-X, Song Z-G, Jin H (2014b). Decreased expression of miR216a contributes to non–small-cell lung cancer progression. Clinical Cancer Research 20: 4705-4716. doi: 10.1158/1078-0432.CCR-14-0517
Wang X, Li M, Wang Z, Han S, Tang X et al. (2015b). Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. Journal of Biological Chemistry 290: 3925-3935. doi: 10.1074/jbc.M114.596866
Xu D, Ma P, Gao G, Gui Y, Niu X et al. (2015). MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells. Tumor Biology 36: 7743-7753. doi: 10.1007/s13277-015-3378-2
Xu Z, Zeng X, Tian D, Xu H, Cai Q et al. (2014). MicroRNA-383 inhibits anchorage-independent growth and induces cell cycle arrest of glioma cells by targeting CCND1. Biochemical and Biophysical Research Communications 453: 833-838. doi: 10.1016/j.bbrc.2014.10.047
Yamada Y, Hidaka H, Seki N, Yoshino H, Yamasaki T et al. (2013). Tumor‐suppressive microRNA‐135a inhibits cancer cell proliferation by targeting the c‐MYC oncogene in renal cell carcinoma. Cancer Science 104: 304-312. doi: 10.1111/cas.12072